Talk:Florbetaben (18F)

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Florbetaben (18F).

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Hi - I am writing from Piramal to give an update on the status on Florbetaben (18F) as it is now approved in both the U.S. and the E.U. I'm including more details and citations: In February, Florbetaben was approved for commercial marketing in the EU: ^[1]

Florbetaben was approved by the FDA in March of this year: ^[2]

As you will see in those article, it's commercial name is Neuraceq™.

I am happy to update the article but thought perhaps I'd start by sharing the information here.

Thanks Emilyfisher boston (talk) 12:32, 29 September 2014 (UTC)Reply

COI Tag

Latest comment: 6 years ago1 comment1 person in discussion

The body of this article appears to have been written to advertise the use of this tracer in US clinical practice by amyloidbrainimaging, a user whose only edit is this article. The article needs editing to provide a balanced review of the evidence for this intervention rather than simply the views of the company that developed it. Friend of a friends (talk) 08:28, 22 March 2018 (UTC)Reply

Add topic

[1] ttp://www.molecularimaging.net/topics/molecular-imaging/biomarkers/neuraceq-gets-european-approval-amyloid-pet-imaging

[2] ttp://www.molecularimaging.net/topics/molecular-imaging/neuroimaging/fda-approves-neuraceq-amyloid-pet-agent

[1]

[2]